Inventiva S.A.
NASDAQ: IVA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Obenshain
- Employees
- 114
- Headquarters
- Daix, France
- IPO year
- 2020
- Market cap
- $179.9M
- Website
- https://www.inventivapharma.com
Loading IVA…
Loading profile data…Frequently asked questions about IVA
What does Inventiva S.A. (IVA) do?
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The c...
Where does IVA trade?
Inventiva S.A. (IVA) trades on the NASDAQ Global Market.
What sector is IVA in?
Inventiva S.A. (IVA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Inventiva S.A.?
Andrew Obenshain is the chief executive officer of Inventiva S.A. (IVA).
Where is Inventiva S.A. headquartered?
Inventiva S.A. is headquartered in France.
Does IVA pay a dividend?
Inventiva S.A. (IVA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IVA go public?
Inventiva S.A. (IVA) completed its initial public offering in 2020.
Is IVA an ADR?
Yes — IVA is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Inventiva S.A. reporting and dividends follow the underlying issuer.